Advanced Therapies Week 2022 | The advantages of the CABA™ platform for treating B-cell-mediated autoimmune diseases

Samik Basu, MD, Cabaletta Bio, Philadelphia, PA, comments on the benefits of the Cabaletta Approach to selective B cell Ablation (CABA™) platform over standard of care treatments for B-cell-mediated autoimmune diseases such as rituximab or steroids, which result in broad immunosuppression which may be dangerous for patients. The CABA™ platform selectively eliminates specific autoantibody-producing B cells, minimizing adverse events and avoiding immunosuppression. This interview took place at Advanced Therapies Week 2022.